<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00360698</url>
  </required_header>
  <id_info>
    <org_study_id>HMR1964A_4002</org_study_id>
    <secondary_id>EUDRACT # : 2005-002614-38</secondary_id>
    <nct_id>NCT00360698</nct_id>
  </id_info>
  <brief_title>Insulin Glulisine in Type 2 Diabetic Patients</brief_title>
  <acronym>Basal Plus</acronym>
  <official_title>Comparison of Two Therapeutic Strategies for Treating Type 2 Diabetic Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs : 6-month Proof of Concept Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of a single injection of glulisine before the main meal added to
      insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs
      in Type 2 diabetic patients poorly controlled with basal insulin plus OADs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients With Glycosylated Haemoglobin (HbA1c) Value &lt; 7%</measure>
    <time_frame>at the end of treatment (week 24)</time_frame>
    <description>Glycosylated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow -up in diabetic patients. this parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c &lt;7%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycosylated Haemoglobin (HbA1c) Value</measure>
    <time_frame>at the end of treatment (week 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycosylated Haemoglobin (HbA1c) Value</measure>
    <time_frame>from baseline to the end of treatment (week 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Mean Plasma Glucose</measure>
    <time_frame>at the end of treatment (week 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Daily Mean Plasma Glucose</measure>
    <time_frame>from baseline to the end of treatment (week 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>from baseline to the end of treatment (week 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Dose of Insulin Glargine</measure>
    <time_frame>at the end of treatment (week 24)</time_frame>
    <description>Mean of 3 daily doses reported during the week prior to the final visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Dose of Insulin Glulisine</measure>
    <time_frame>at the end of treatment (week 24)</time_frame>
    <description>Mean of 3 daily doses reported during the week prior to the final visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Symptomatic Hypoglycemia With Plasma Glucose &lt; 70mg/dL</measure>
    <time_frame>during treatment period (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Nocturnal Symptomatic Hypoglycemia With Plasma Glucose &lt; 70mg/dL</measure>
    <time_frame>during treatment period (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Severe Symptomatic Hypoglycemia</measure>
    <time_frame>during treatment period (12 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>insulin glulisine+insulin glargine+metformin+glimepiride</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bolus arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>insulin glargine+metformin+glimepiride</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>One daily injection at bedtime</description>
    <arm_group_label>insulin glulisine+insulin glargine+metformin+glimepiride</arm_group_label>
    <arm_group_label>insulin glargine+metformin+glimepiride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>At same dosage as during the run-in period</description>
    <arm_group_label>insulin glulisine+insulin glargine+metformin+glimepiride</arm_group_label>
    <arm_group_label>insulin glargine+metformin+glimepiride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glulisine</intervention_name>
    <description>One bolus given before the main meal</description>
    <arm_group_label>insulin glulisine+insulin glargine+metformin+glimepiride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>At same dosage as during the run-in period</description>
    <arm_group_label>insulin glulisine+insulin glargine+metformin+glimepiride</arm_group_label>
    <arm_group_label>insulin glargine+metformin+glimepiride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes Mellitus, Type 2

          -  25 &lt; BMI &lt; 45 kg/m²

          -  7,5% &lt; HbA1c &lt; 9%

          -  Treated with a basal insulin (NPH, Insulin Zinc, Insulin glargine or Insulin detemir),
             and at least 1g metformin daily, for more than 3 months

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Treatment with OADs only

          -  Treatment with thiazolidinediones, with exenatide or with pramlintide

          -  Treatment with an insulin other than basal insulin (Premix, rapid insulin, fast-acting
             insulin analogue)

          -  Active proliferative diabetic retinopathy,

          -  Pregnancy (women of childbearing potential must have a negative pregnancy test at
             study entry and effective contraception)

          -  Breast-feeding

          -  History of hypersensitivity to the study drugs or to drugs with a similar chemical
             structure.

          -  Treatment with systemic corticosteroids in the 3 months prior to study entry

          -  Treatment with any investigational product in the 2 months prior to study entry

          -  Previous treatment with insulin glulisine

          -  Likelihood of requiring treatment during the study period with drugs not permitted by
             the clinical study protocol

          -  Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major
             disease making implementation of the protocol or interpretation of the study results
             difficult

          -  Impaired hepatic function

          -  Impaired renal function

          -  History of drug or alcohol abuse

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PILORGET Valérie, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
  </removed_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2006</study_first_submitted>
  <study_first_submitted_qc>August 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2006</study_first_posted>
  <results_first_submitted>August 20, 2009</results_first_submitted>
  <results_first_submitted_qc>October 27, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2009</results_first_posted>
  <last_update_submitted>August 1, 2011</last_update_submitted>
  <last_update_submitted_qc>August 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Trial Transparency Team</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>During Run-In period patients were not assigned to a treatment group. They were all treated with Insulin Glargine + Metformin + Glimepiride.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride</title>
          <description>Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
        </group>
        <group group_id="P2">
          <title>Insulin Glargine+Metformin+Glimepiride</title>
          <description>Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Run-In</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="125">19 patients completed the run-in but were not eligible for randomization in the treatment period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliance with treatment procedure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor request</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient did not meet inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Need of insulin with meals</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non compliance with treatment procedure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early termination by error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride</title>
          <description>Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
        </group>
        <group group_id="B2">
          <title>Insulin Glargine+Metformin+Glimepiride</title>
          <description>Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="106"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.6" spread="6.73"/>
                    <measurement group_id="B2" value="59.3" spread="8.84"/>
                    <measurement group_id="B3" value="59.9" spread="7.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Total patients analyzed n=105 due to one missing data in the &quot;insulin glulisine+insulin glargine+metformin+glimepiride&quot; group</description>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2" spread="5.30"/>
                    <measurement group_id="B2" value="33.3" spread="4.39"/>
                    <measurement group_id="B3" value="33.3" spread="4.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily Mean Plasma Glucose</title>
          <description>Patients having a baseline value and a value on treatment:
insulin glulisine+insulin glargine+metformin+glimepiride group n=47 patients, insulin glargine+metformin+glimepiride group n=55 patients</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.2" spread="27.86"/>
                    <measurement group_id="B2" value="167.4" spread="39.41"/>
                    <measurement group_id="B3" value="169" spread="34.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.1" spread="7.29"/>
                    <measurement group_id="B2" value="11.0" spread="7.02"/>
                    <measurement group_id="B3" value="11.5" spread="7.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Haemoglobin (HbA1c)</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.8" spread="0.60"/>
                    <measurement group_id="B2" value="8.0" spread="0.67"/>
                    <measurement group_id="B3" value="7.9" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>Total patients analyzed n=105 due to one missing data in the &quot;insulin glulisine+insulin glargine+metformin+glimepiride&quot; group</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.5" spread="16.60"/>
                    <measurement group_id="B2" value="92.9" spread="17.15"/>
                    <measurement group_id="B3" value="92.3" spread="16.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patients With Glycosylated Haemoglobin (HbA1c) Value &lt; 7%</title>
        <description>Glycosylated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow -up in diabetic patients. this parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c &lt;7%</description>
        <time_frame>at the end of treatment (week 24)</time_frame>
        <population>Modified Intent to treat (ITT) population, LOCF (Last Observation Carried Forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Glycosylated Haemoglobin (HbA1c) Value &lt; 7%</title>
          <description>Glycosylated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow -up in diabetic patients. this parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c &lt;7%</description>
          <population>Modified Intent to treat (ITT) population, LOCF (Last Observation Carried Forward)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4"/>
                    <measurement group_id="O2" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null-hypothesis stated no differences between the 2 treatment groups regarding the percentage of patients with Glycosylated Haemoglobin (HbA1c) level &lt;7%. A sample size of 98 randomized (49/arm) patients would allow to demonstrate with 80% power that 40 % of patients in the Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride group would achieve a HbA1c level &lt; 7 % compared to 15 % of patients in the Insulin Glargine+Metformin+Glimepiride group(5% alpha risk, 2-sided test).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0499</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>13.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>28.37</ci_upper_limit>
            <estimate_desc>Difference in percentage between groups: Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride group - Insulin Glargine+Metformin+Glimepiride group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycosylated Haemoglobin (HbA1c) Value</title>
        <time_frame>at the end of treatment (week 24)</time_frame>
        <population>Modified ITT population, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
        </group_list>
        <measure>
          <title>Glycosylated Haemoglobin (HbA1c) Value</title>
          <population>Modified ITT population, LOCF</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="0.64"/>
                    <measurement group_id="O2" value="7.8" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glycosylated Haemoglobin (HbA1c) Value</title>
        <time_frame>from baseline to the end of treatment (week 24)</time_frame>
        <population>Modified ITT population, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycosylated Haemoglobin (HbA1c) Value</title>
          <population>Modified ITT population, LOCF</population>
          <units>percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.085"/>
                    <measurement group_id="O2" value="-0.11" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null-hypothesis stated no difference between the 2 treatment groups regarding the adjusted mean change from baseline in Glycosylated Haemoglobin (HbA1c) at the end of treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The analysis is an ANCOVA analysis on the change with group as fixed effect and baseline HbA1c as covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.116</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
            <estimate_desc>Difference between groups: Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride group - Insulin Glargine+Metformin+Glimepiride group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Mean Plasma Glucose</title>
        <time_frame>at the end of treatment (week 24)</time_frame>
        <population>Modified ITT population, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Mean Plasma Glucose</title>
          <population>Modified ITT population, LOCF</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.7" spread="28.62"/>
                    <measurement group_id="O2" value="165.8" spread="37.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Daily Mean Plasma Glucose</title>
        <time_frame>from baseline to the end of treatment (week 24)</time_frame>
        <population>Modified ITT population, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Daily Mean Plasma Glucose</title>
          <population>Modified ITT population, LOCF</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.01" spread="3.661"/>
                    <measurement group_id="O2" value="-2.07" spread="3.384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null-hypothesis stated no differences between the 2 treatment groups regarding the adjusted mean change from baseline in daily mean plasma glucose at the end of treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0109</p_value>
            <p_value_desc>Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The analysis is an ANCOVA analysis on the change with group as fixed effect and baseline daily mean plasma glucose as covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-12.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.987</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-22.83</ci_lower_limit>
            <ci_upper_limit>-3.04</ci_upper_limit>
            <estimate_desc>Difference between groups: Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride group - Insulin Glargine+Metformin+Glimepiride group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight</title>
        <time_frame>from baseline to the end of treatment (week 24)</time_frame>
        <population>Modified ITT population, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight</title>
          <population>Modified ITT population, LOCF</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.316"/>
                    <measurement group_id="O2" value="0.22" spread="0.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null-hypothesis stated no differences between the 2 treatment groups regarding the adjusted mean change from baseline in weight at the end of treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5762</p_value>
            <p_value_desc>Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The analysis is an ANCOVA analysis on the change with group as fixed effect and baseline weight as covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.431</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>Difference between groups: Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride group - Insulin Glargine+Metformin+Glimepiride group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Dose of Insulin Glargine</title>
        <description>Mean of 3 daily doses reported during the week prior to the final visit</description>
        <time_frame>at the end of treatment (week 24)</time_frame>
        <population>Modified ITT population, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Dose of Insulin Glargine</title>
          <description>Mean of 3 daily doses reported during the week prior to the final visit</description>
          <population>Modified ITT population, LOCF</population>
          <units>units of insulin glargine per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7" spread="34.84"/>
                    <measurement group_id="O2" value="62.2" spread="34.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Dose of Insulin Glulisine</title>
        <description>Mean of 3 daily doses reported during the week prior to the final visit</description>
        <time_frame>at the end of treatment (week 24)</time_frame>
        <population>Modified ITT population, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Dose of Insulin Glulisine</title>
          <description>Mean of 3 daily doses reported during the week prior to the final visit</description>
          <population>Modified ITT population, LOCF</population>
          <units>units of insulin glulisine per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="6.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Symptomatic Hypoglycemia With Plasma Glucose &lt; 70mg/dL</title>
        <time_frame>during treatment period (12 weeks)</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Symptomatic Hypoglycemia With Plasma Glucose &lt; 70mg/dL</title>
          <population>Safety population</population>
          <units>Number of hypoglycemia per patient-year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.19" spread="14.603"/>
                    <measurement group_id="O2" value="7.68" spread="13.996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null-hypothesis stated no difference between the 2 treatment groups regarding the rate of symptomatic hypoglycemia with plasma glucose &lt;70 mg/dL during the treatment period.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.958</p_value>
            <p_value_desc>Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Nocturnal Symptomatic Hypoglycemia With Plasma Glucose &lt; 70mg/dL</title>
        <time_frame>during treatment period (12 weeks)</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Nocturnal Symptomatic Hypoglycemia With Plasma Glucose &lt; 70mg/dL</title>
          <population>Safety population</population>
          <units>Number of hypoglycemia per patient-year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="3.418"/>
                    <measurement group_id="O2" value="3.95" spread="9.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null-hypothesis stated no difference between the 2 treatment groups regarding the rate of nocturnal symptomatic hypoglycemia with plasma glucose &lt;70 mg/dL during the treatment period.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.302</p_value>
            <p_value_desc>Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Severe Symptomatic Hypoglycemia</title>
        <time_frame>during treatment period (12 weeks)</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine+Metformin+Glimepiride</title>
            <description>Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Severe Symptomatic Hypoglycemia</title>
          <population>Safety population</population>
          <units>Number of hypoglycemia per patient-year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.000"/>
                    <measurement group_id="O2" value="0.20" spread="1.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null-hypothesis stated no difference between the 2 treatment groups regarding the rate of severe symptomatic hypoglycemia during the treatment period.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.192</p_value>
            <p_value_desc>Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride</title>
          <description>Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
        </group>
        <group group_id="E2">
          <title>Insulin Glargine+Metformin+Glimepiride</title>
          <description>Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scleroderma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Tendon Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs study director</name_or_title>
      <organization>sanofi-aventis</organization>
      <email>publicregistryGMA@sanofi-aventis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

